Welcoming Michael González-Durruthy to the group

Dr. Michael González-Durruthy was hired to work on the project entitled iDrugCF: Identification of New Drugs for Cystic Fibrosis. This project is financed by the Portuguese Science Foundation (FCT) to discover and develop novel molecules able to rescue and potentiate Read more ›

Optimizing the macrocyclic diterpenic core toward the reversal of multidrug resistance in cancer

Background: From a dataset obtained by chemical derivatization of a macrocyclic diterpenic scaffold, in silico approaches identified which structural features correlate with experimental modulation of P-gp activity. Results/methodology: Ninety-two percent of the strongest MDR modulators were positively identified within the Read more ›

Reversing cancer multidrug resistance: insights into the efflux by ABC transports from in silico studies

One of the greatest threats to cancer treatment is the development, by some tumors, of resistance to the pharmacological action of several structurally unrelated cytotoxic agents—multidrug resistance (MDR). As P-glycoprotein (P-gp) is one of the most studied ATP-dependent efflux pumps Read more ›